Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




The Prostatome – a Novel Prostate Atlas Combining Anatomic and Disease Pathology Data Founded

By LabMedica International staff writers
Posted on 23 Jul 2014
Scientists have succeeded in fusing prostate cancer pathology data with anatomical magnetic resonance imaging (MRI) data to create the foundation of a first-of-its-kind prostate atlas for prostate cancer.

A team of scientists and clinicians, led by Anant Madabhushi, professor of biomedical engineering and director of the Center of Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University (Cleveland, OH, USA), developed a novel framework, the anatomically constrained registration (AnCoR) scheme, and applied it to perform the fusion of initial data sets for creating the new prostate cancer (PrCa) "prostatome" atlas. More...
The methods developed in the study can now be applied with a larger sample size data set to create a more fully developed atlas, which will allow for highly accurate identification of the MRI signatures associated with PrCa extent and aggressiveness.

The atlas was constructed and validated on 80 patients from two different sites—Boston Medical Center and Beth Israel Deaconess Medical Center. The goal of the study was to integrate pathology and MRI data from multiple different PrCa patients who had undergone surgery involving complete removal of the prostate (radical prostatectomy). All patients had an MRI performed before surgery. The methods developed in this project were used to fuse the MRI scans obtained before surgery with histology data of the surgically excised specimens. This allowed for mapping of cancer extent (determined by a pathologist) in the surgically excised specimen onto the preoperative imaging, enabling construction of a novel PrCa MRI atlas that incorporates PrCa specimen information.

Prof. Madabhushi commented, “The prostatome atlas could allow for integrating imaging data from multiple different patients studies into one unified representation and thereby allow for guiding biopsies, specific treatment targeting, and also serve as an educational tool for medical students and residents.” Additionally, the AnCoR framework could allow for incorporation of complementary imaging and molecular data, thereby enabling their careful correlation for population based radio-omics.

The study, by Rusu M. et al., was described in the July, 2014, issue of the journal Medical Physics.

Related Links:
Case Western Reserve University
Center of Computational Imaging and Personalized Diagnostics




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.